PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer
Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on...
Saved in:
| Published in | BMC cancer Vol. 19; no. 1; pp. 506 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
28.05.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression.
PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome.
In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination.
EU Clinical Trials Register: EudraCT 2016-001569-97 , registered on 19-6-2017. Clinicaltrials.gov: NCT03192059 , registered on 19-6-2017. |
|---|---|
| AbstractList | Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression.
PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome.
In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination.
EU Clinical Trials Register: EudraCT 2016-001569-97 , registered on 19-6-2017. Clinicaltrials.gov: NCT03192059 , registered on 19-6-2017. Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression.BACKGROUNDImmunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression.PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome.METHODSPRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome.In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination.DISCUSSIONIn this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination.EU Clinical Trials Register: EudraCT 2016-001569-97 , registered on 19-6-2017. Clinicaltrials.gov: NCT03192059 , registered on 19-6-2017.TRIAL REGISTRATIONEU Clinical Trials Register: EudraCT 2016-001569-97 , registered on 19-6-2017. Clinicaltrials.gov: NCT03192059 , registered on 19-6-2017. Background Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13–17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression. Methods PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome. Discussion In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination. Trial registration EU Clinical Trials Register: EudraCT 2016-001569-97, registered on 19-6-2017. Clinicaltrials.gov: NCT03192059, registered on 19-6-2017. Background Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression. Methods PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 x 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome. Discussion In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination. Trial registration EU Clinical Trials Register: EudraCT 2016-001569-97, registered on 19-6-2017. Clinicaltrials.gov: NCT03192059, registered on 19-6-2017. Keywords: PD-1 blockade, Radiation, Immune modulation, Tumor microenvironment, Cervical carcinoma, Endometrial carcinoma, Uterine sarcoma, Drug repurposing, Metronomic chemotherapy, Financial toxicity Abstract Background Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13–17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food supplement. We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an anti-tumor immune response, resulting in tumor regression. Methods PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2 weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles. Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose. The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity. The primary objective is objective response rate at week 26 according to immune-related response criteria. Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall response, progression-free survival, overall survival and quality of life. Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers and the gut microbiome. Discussion In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination. Trial registration EU Clinical Trials Register: EudraCT 2016-001569-97, registered on 19-6-2017. Clinicaltrials.gov: NCT03192059, registered on 19-6-2017. Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13-17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tumor vasculature. PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma. In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational research is performed to discover biomarkers related to the mode of action of the combination. |
| ArticleNumber | 506 |
| Audience | Academic |
| Author | Aspeslagh, Sandrine Tuyaerts, Sandra Dirix, Piet De Caluwé, Alex Vandecasteele, Katrien Vuylsteke, Peter De Jaeghere, Emiel Denys, Hannelore Van Dam, Peter A Amant, Frédéric Lippens, Lien Naert, Eline Van Nuffel, An M T |
| Author_xml | – sequence: 1 givenname: Sandra orcidid: 0000-0003-1255-8071 surname: Tuyaerts fullname: Tuyaerts, Sandra email: sandra.tuyaerts@kuleuven.be, sandra.tuyaerts@kuleuven.be organization: Leuven Cancer Institute (LKI), Leuven, Belgium. sandra.tuyaerts@kuleuven.be – sequence: 2 givenname: An M T surname: Van Nuffel fullname: Van Nuffel, An M T organization: Anticancer Fund, Strombeek-Bever, Belgium – sequence: 3 givenname: Eline surname: Naert fullname: Naert, Eline organization: Cancer Research Institute Gent (CRIG), Ghent, Belgium – sequence: 4 givenname: Peter A surname: Van Dam fullname: Van Dam, Peter A organization: Division of Gynecologic Oncology and Senology, University Hospital Antwerp, Antwerp, Belgium – sequence: 5 givenname: Peter surname: Vuylsteke fullname: Vuylsteke, Peter organization: Division of Oncology, CHU UCL Namur, Sainte Elisabeth, Namur, Belgium – sequence: 6 givenname: Alex surname: De Caluwé fullname: De Caluwé, Alex organization: Division of Radiation Oncology, Institut Jules Bordet, Brussels, Belgium – sequence: 7 givenname: Sandrine surname: Aspeslagh fullname: Aspeslagh, Sandrine organization: Division of Radiation Oncology, Institut Jules Bordet, Brussels, Belgium – sequence: 8 givenname: Piet surname: Dirix fullname: Dirix, Piet organization: Division of Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO), University of Antwerp, Antwerp, Belgium – sequence: 9 givenname: Lien surname: Lippens fullname: Lippens, Lien organization: Cancer Research Institute Gent (CRIG), Ghent, Belgium – sequence: 10 givenname: Emiel surname: De Jaeghere fullname: De Jaeghere, Emiel organization: Cancer Research Institute Gent (CRIG), Ghent, Belgium – sequence: 11 givenname: Frédéric surname: Amant fullname: Amant, Frédéric organization: Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam, the Netherlands – sequence: 12 givenname: Katrien surname: Vandecasteele fullname: Vandecasteele, Katrien organization: Division of Radiation Oncology, UZ Gent, Ghent, Belgium – sequence: 13 givenname: Hannelore surname: Denys fullname: Denys, Hannelore email: hannelore.denys@uzgent.be, hannelore.denys@uzgent.be organization: Cancer Research Institute Gent (CRIG), Ghent, Belgium. hannelore.denys@uzgent.be |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31138229$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkt1qFDEYhgep2B-9AE9kQBAFp-ZnMpPpgVDq30BLS9Xj8E2S2c12JlmTTLEX4H2b7a51VySQhDfP9yb5eA-zPeuszrLnGB1jzKt3ARPOWYFwU7Cqrgr6KDvAZY0LUqJ6b2u_nx2GsEAI1xzxJ9k-xZhyQpqD7NfVdXtxcZmHOKm7fOlddNINJznkyzkEnbft5ki6sTPW2Fl-9aHAeTc4eQNKv809KAPROJuDVbkZx8m60alpWIvR5RHkzaBzqf2tkTDcc1PU3tgkgk360-xxD0PQzzbrUfb908dvZ1-K88vP7dnpeSErwmJREU246jmHBlWMUo4bXCPJe1xWmrMeMU5lybtSdqonJShcsV7xSuEOE1QhepS1a1_lYCGW3ozg74QDI-4F52cCfDRy0EIB5qzBoDiCEvWI1zUHqcuG9ZRR1SSv92uv5dSNWklto4dhx3T3xJq5mLlbkV5eE1Qng9cbA-9-TDpEMZog9TCA1W4KghCankBKzhL68h904SZvU6sSVVJSsYY3f6kZpA8Y27t0r1yZilPWoBqladWD4_9QaSg9GpkC1puk7xS82SlITNQ_4wymEET79XqXfbXFzjUMcR7cMK2iEHZBvAaldyF43T80DiOxCrdYh1ukcItVuAVNNS-2O_5Q8SfN9DcXJ_Mh |
| CitedBy_id | crossref_primary_10_1016_j_semcancer_2022_06_009 crossref_primary_10_1007_s00018_023_05098_8 crossref_primary_10_1166_sam_2021_4003 crossref_primary_10_3389_fonc_2022_785350 crossref_primary_10_1002_med_21876 crossref_primary_10_3390_ijms241612587 crossref_primary_10_3389_fimmu_2023_1061761 crossref_primary_10_3390_ijms21145034 crossref_primary_10_1016_j_intimp_2023_111199 crossref_primary_10_3892_ol_2020_11774 crossref_primary_10_1016_j_pharmthera_2020_107700 crossref_primary_10_3390_nu14010032 crossref_primary_10_1186_s13046_023_02598_0 crossref_primary_10_3389_fimmu_2023_1135657 crossref_primary_10_3390_ijms21113761 crossref_primary_10_3389_fonc_2022_849352 crossref_primary_10_1155_2022_8092751 crossref_primary_10_2217_fon_2020_0994 crossref_primary_10_2174_0929867327999200817104912 crossref_primary_10_3390_ijms22168936 crossref_primary_10_1016_j_semcancer_2020_06_014 crossref_primary_10_18632_aging_104083 crossref_primary_10_1016_j_clon_2020_06_010 crossref_primary_10_3389_fonc_2020_595351 crossref_primary_10_2147_CMAR_S285560 crossref_primary_10_12677_ACM_2023_1381734 crossref_primary_10_4167_jbv_2019_49_4_162 crossref_primary_10_1016_j_ejso_2020_05_026 crossref_primary_10_1016_j_biopha_2022_114057 crossref_primary_10_3892_ol_2023_14210 crossref_primary_10_1002_cti2_1335 crossref_primary_10_3389_fonc_2022_1045481 crossref_primary_10_1007_s00262_022_03253_x crossref_primary_10_1016_j_ijrobp_2020_09_016 crossref_primary_10_3390_ijms222011061 crossref_primary_10_4155_ppa_2020_0017 crossref_primary_10_3390_ijms24065159 crossref_primary_10_3389_fonc_2022_838637 crossref_primary_10_3390_cancers14235785 crossref_primary_10_1016_j_tjog_2022_08_021 crossref_primary_10_3390_biomedicines9060632 crossref_primary_10_3390_ijms241813985 |
| Cites_doi | 10.1016/S1470-2045(15)00486-6 10.1016/j.immuni.2017.02.001 10.1001/jamaoncol.2015.0373 10.1158/1078-0432.CCR-16-1031 10.3390/molecules16064567 10.1111/cts.12070 10.1007/s00281-011-0245-0 10.1016/j.humimm.2010.04.008 10.1001/jamaoncol.2015.2151 10.1200/JCO.2018.36.15_suppl.5522 10.1016/S0198-8859(01)00317-2 10.1038/nrc.2017.77 10.1080/2162402X.2016.1264565 10.1016/j.otohns.2008.11.011 10.1038/nrclinonc.2017.31 10.1158/1078-0432.CCR-15-0057 10.1158/0008-5472.CAN-11-1272 10.1200/JCO.2017.76.2229 10.1016/j.cbi.2013.10.007 10.1186/s13569-016-0064-0 10.1038/nrc3958 10.1016/j.cell.2015.08.015 10.1016/j.ccell.2016.10.010 10.18632/oncotarget.20877 10.4161/onci.22058 10.1007/s00280-017-3426-2 10.1016/j.ygyno.2017.06.005 10.1038/nrclinonc.2015.209 10.1016/j.ctrv.2016.11.013 10.3322/caac.21262 10.2165/00003495-200767060-00001 10.1172/JCI84940 10.1016/j.critrevonc.2011.04.009 10.1002/ijc.29210 10.1016/j.jsbmb.2014.10.007 10.1016/j.virol.2008.11.046 10.1093/annonc/mdx220 10.1158/1078-0432.CCR-17-0895 10.1158/1535-7163.MCT-15-0066 10.3389/fonc.2014.00325 10.1016/j.ajog.2011.03.008 10.1038/nature13954 10.1016/j.canlet.2015.05.012 10.1126/science.359.6382.1346 10.1007/s00262-003-0459-7 10.1200/JOP.2013.001351 10.1002/cncr.30738 10.1158/0008-5472.CAN-14-1258 10.1158/2326-6066.CIR-13-0141 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-019-5676-3 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_da18591ad80a40f08778ace495f353d9 A590705900 10_1186_s12885_019_5676_3 31138229 |
| Genre | Multicenter Study Clinical Trial, Phase II Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Kom op tegen Kanker grantid: not applicable – fundername: Anticancer Fund grantid: not applicable – fundername: ; grantid: not applicable |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO ABVAZ AFNRJ 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c625t-62e28df88a906533819170c8f146e85f0583c48b4cbdf24ad165fd86d1b120603 |
| IEDL.DBID | RPM |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 22 15:15:30 EDT 2024 Tue Sep 17 21:26:49 EDT 2024 Sat Oct 26 04:38:29 EDT 2024 Thu Oct 10 18:28:13 EDT 2024 Thu Feb 22 23:34:52 EST 2024 Fri Feb 02 04:25:16 EST 2024 Thu Aug 01 20:18:24 EDT 2024 Tue Aug 20 22:11:14 EDT 2024 Thu Sep 12 17:02:21 EDT 2024 Tue Oct 29 09:17:25 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Financial toxicity Tumor microenvironment Metronomic chemotherapy Radiation Drug repurposing PD-1 blockade Uterine sarcoma Cervical carcinoma Endometrial carcinoma Immune modulation |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c625t-62e28df88a906533819170c8f146e85f0583c48b4cbdf24ad165fd86d1b120603 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0003-1255-8071 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537207/ |
| PMID | 31138229 |
| PQID | 2243265989 |
| PQPubID | 44074 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_da18591ad80a40f08778ace495f353d9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6537207 proquest_miscellaneous_2231852485 proquest_journals_2243265989 gale_infotracmisc_A590705900 gale_infotracacademiconefile_A590705900 gale_incontextgauss_ISR_A590705900 gale_healthsolutions_A590705900 crossref_primary_10_1186_s12885_019_5676_3 pubmed_primary_31138229 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-28 |
| PublicationDateYYYYMMDD | 2019-05-28 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | N Penel (5676_CR43) 2012; 82 JS Kulbersh (5676_CR30) 2009; 140 C Corbet (5676_CR39) 2017; 17 PC Tumeh (5676_CR19) 2014; 515 HC Chung (5676_CR5) 2018; 36 5676_CR3 Z Liao (5676_CR35) 2007; 67 FA Eggink (5676_CR9) 2017; 6 R Salani (5676_CR7) 2011; 204 E Ben-Ami (5676_CR18) 2017; 123 JJ Luke (5676_CR21) 2018; 36 M Bellone (5676_CR41) 2013; 2 A Sistigu (5676_CR44) 2011; 33 CE Holmes (5676_CR38) 2013; 6 DM Lathers (5676_CR32) 2001; 62 Martin Scurr (5676_CR45) 2017; 23 Gunjal Garg (5676_CR8) 2012 S George (5676_CR17) 2017; 46 L Paoluzzi (5676_CR16) 2016; 6 A Shehzad (5676_CR46) 2013; 206 AD Santin (5676_CR12) 2016; 22 J Kaiser (5676_CR50) 2018; 359 S Mailankody (5676_CR51) 2015; 1 T Hamada (5676_CR37) 2017; 8 H zur Hausen (5676_CR4) 2009; 384 SG Kroeze (5676_CR22) 2017; 53 WH van Harten (5676_CR52) 2016; 17 Y Jeong (5676_CR34) 2015; 14 V Prasad (5676_CR49) 2017; 14 C Marth (5676_CR2) 2017; 28 HE Barker (5676_CR27) 2015; 15 SJ Dovedi (5676_CR24) 2014; 74 RE Vatner (5676_CR25) 2014; 4 IC van Gool (5676_CR11) 2015; 21 A Calcinotto (5676_CR42) 2012; 72 BE Howitt (5676_CR10) 2015; 1 S Zelenay (5676_CR36) 2015; 162 T Cuppens (5676_CR15) 2017; 146 LA Torre (5676_CR1) 2015; 65 Zhen-Ning Lu (5676_CR40) 2017; 80 JY Chern (5676_CR14) 2017; 31 H Kantarjian (5676_CR53) 2014; 10 P Basnet (5676_CR47) 2011; 16 JY So (5676_CR33) 2015; 148 MM Ahmed (5676_CR26) 2013; 1 SO Lim (5676_CR48) 2016; 30 DM Lathers (5676_CR31) 2004; 53 JM Mehnert (5676_CR13) 2016; 126 JE Walsh (5676_CR29) 2010; 71 F Teng (5676_CR23) 2015; 365 J Ferlay (5676_CR6) 2015; 136 E Zhuravel (5676_CR28) 2010; 32 MJ Smyth (5676_CR20) 2016; 13 |
| References_xml | – volume: 17 start-page: 18 year: 2016 ident: 5676_CR52 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00486-6 contributor: fullname: WH van Harten – volume: 46 start-page: 197 year: 2017 ident: 5676_CR17 publication-title: Immunity doi: 10.1016/j.immuni.2017.02.001 contributor: fullname: S George – volume: 1 start-page: 539 year: 2015 ident: 5676_CR51 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.0373 contributor: fullname: S Mailankody – volume: 22 start-page: 5682 year: 2016 ident: 5676_CR12 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1031 contributor: fullname: AD Santin – volume: 16 start-page: 4567 year: 2011 ident: 5676_CR47 publication-title: Molecules doi: 10.3390/molecules16064567 contributor: fullname: P Basnet – volume: 31 start-page: 229 year: 2017 ident: 5676_CR14 publication-title: Oncology (Williston Park) contributor: fullname: JY Chern – volume: 6 start-page: 386 year: 2013 ident: 5676_CR38 publication-title: Clin Transl Sci doi: 10.1111/cts.12070 contributor: fullname: CE Holmes – volume: 33 start-page: 369 year: 2011 ident: 5676_CR44 publication-title: Semin Immunopathol doi: 10.1007/s00281-011-0245-0 contributor: fullname: A Sistigu – volume: 71 start-page: 659 year: 2010 ident: 5676_CR29 publication-title: Hum Immunol doi: 10.1016/j.humimm.2010.04.008 contributor: fullname: JE Walsh – volume-title: Cancer of the Uterine Endometrium - Advances and Controversies year: 2012 ident: 5676_CR8 contributor: fullname: Gunjal Garg – volume: 1 start-page: 1319 issue: 9 year: 2015 ident: 5676_CR10 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.2151 contributor: fullname: BE Howitt – volume: 36 start-page: abstract 5522 year: 2018 ident: 5676_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.5522 contributor: fullname: HC Chung – volume: 62 start-page: 1282 year: 2001 ident: 5676_CR32 publication-title: Hum Immunol doi: 10.1016/S0198-8859(01)00317-2 contributor: fullname: DM Lathers – volume: 17 start-page: 577 year: 2017 ident: 5676_CR39 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.77 contributor: fullname: C Corbet – volume: 6 start-page: e1264565 year: 2017 ident: 5676_CR9 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1264565 contributor: fullname: FA Eggink – volume: 140 start-page: 235 year: 2009 ident: 5676_CR30 publication-title: Otolaryngol Head Neck Surg doi: 10.1016/j.otohns.2008.11.011 contributor: fullname: JS Kulbersh – volume: 14 start-page: 381 year: 2017 ident: 5676_CR49 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.31 contributor: fullname: V Prasad – volume: 21 start-page: 3347 year: 2015 ident: 5676_CR11 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0057 contributor: fullname: IC van Gool – volume: 72 start-page: 2746 year: 2012 ident: 5676_CR42 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-1272 contributor: fullname: A Calcinotto – volume: 36 start-page: 1611 year: 2018 ident: 5676_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.2229 contributor: fullname: JJ Luke – volume: 206 start-page: 394 year: 2013 ident: 5676_CR46 publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2013.10.007 contributor: fullname: A Shehzad – volume: 6 start-page: 24 year: 2016 ident: 5676_CR16 publication-title: Clin Sarcoma Res doi: 10.1186/s13569-016-0064-0 contributor: fullname: L Paoluzzi – volume: 15 start-page: 409 year: 2015 ident: 5676_CR27 publication-title: Nat Rev Cancer doi: 10.1038/nrc3958 contributor: fullname: HE Barker – volume: 162 start-page: 1257 year: 2015 ident: 5676_CR36 publication-title: Cell doi: 10.1016/j.cell.2015.08.015 contributor: fullname: S Zelenay – volume: 30 start-page: 925 year: 2016 ident: 5676_CR48 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.10.010 contributor: fullname: SO Lim – volume: 8 start-page: 73370 year: 2017 ident: 5676_CR37 publication-title: Oncotarget doi: 10.18632/oncotarget.20877 contributor: fullname: T Hamada – volume: 2 start-page: e22058 year: 2013 ident: 5676_CR41 publication-title: Oncoimmunology doi: 10.4161/onci.22058 contributor: fullname: M Bellone – volume: 80 start-page: 925 issue: 5 year: 2017 ident: 5676_CR40 publication-title: Cancer Chemotherapy and Pharmacology doi: 10.1007/s00280-017-3426-2 contributor: fullname: Zhen-Ning Lu – volume: 146 start-page: 538 year: 2017 ident: 5676_CR15 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.06.005 contributor: fullname: T Cuppens – volume: 13 start-page: 143 year: 2016 ident: 5676_CR20 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2015.209 contributor: fullname: MJ Smyth – volume: 53 start-page: 25 year: 2017 ident: 5676_CR22 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2016.11.013 contributor: fullname: SG Kroeze – volume: 65 start-page: 87 year: 2015 ident: 5676_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21262 contributor: fullname: LA Torre – volume: 67 start-page: 821 year: 2007 ident: 5676_CR35 publication-title: Drugs doi: 10.2165/00003495-200767060-00001 contributor: fullname: Z Liao – volume: 126 start-page: 2334 year: 2016 ident: 5676_CR13 publication-title: J Clin Invest doi: 10.1172/JCI84940 contributor: fullname: JM Mehnert – volume: 82 start-page: 40 year: 2012 ident: 5676_CR43 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2011.04.009 contributor: fullname: N Penel – volume: 136 start-page: E359 year: 2015 ident: 5676_CR6 publication-title: Int J Cancer doi: 10.1002/ijc.29210 contributor: fullname: J Ferlay – ident: 5676_CR3 – volume: 148 start-page: 79 year: 2015 ident: 5676_CR33 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2014.10.007 contributor: fullname: JY So – volume: 384 start-page: 260 year: 2009 ident: 5676_CR4 publication-title: Virology doi: 10.1016/j.virol.2008.11.046 contributor: fullname: H zur Hausen – volume: 28 start-page: iv72 year: 2017 ident: 5676_CR2 publication-title: Ann Oncol doi: 10.1093/annonc/mdx220 contributor: fullname: C Marth – volume: 23 start-page: 6771 issue: 22 year: 2017 ident: 5676_CR45 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-17-0895 contributor: fullname: Martin Scurr – volume: 14 start-page: 1951 year: 2015 ident: 5676_CR34 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-15-0066 contributor: fullname: Y Jeong – volume: 4 start-page: 325 year: 2014 ident: 5676_CR25 publication-title: Front Oncol doi: 10.3389/fonc.2014.00325 contributor: fullname: RE Vatner – volume: 204 start-page: 466 year: 2011 ident: 5676_CR7 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2011.03.008 contributor: fullname: R Salani – volume: 515 start-page: 568 year: 2014 ident: 5676_CR19 publication-title: Nature doi: 10.1038/nature13954 contributor: fullname: PC Tumeh – volume: 32 start-page: 33 year: 2010 ident: 5676_CR28 publication-title: Exp Oncol contributor: fullname: E Zhuravel – volume: 365 start-page: 23 year: 2015 ident: 5676_CR23 publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.05.012 contributor: fullname: F Teng – volume: 359 start-page: 1346 year: 2018 ident: 5676_CR50 publication-title: Science doi: 10.1126/science.359.6382.1346 contributor: fullname: J Kaiser – volume: 53 start-page: 422 year: 2004 ident: 5676_CR31 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-003-0459-7 contributor: fullname: DM Lathers – volume: 10 start-page: e208 year: 2014 ident: 5676_CR53 publication-title: J Oncol Pract doi: 10.1200/JOP.2013.001351 contributor: fullname: H Kantarjian – volume: 123 start-page: 3285 year: 2017 ident: 5676_CR18 publication-title: Cancer doi: 10.1002/cncr.30738 contributor: fullname: E Ben-Ami – volume: 74 start-page: 5458 year: 2014 ident: 5676_CR24 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-1258 contributor: fullname: SJ Dovedi – volume: 1 start-page: 280 year: 2013 ident: 5676_CR26 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0141 contributor: fullname: MM Ahmed |
| SSID | ssj0017808 |
| Score | 2.5075922 |
| Snippet | Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in... Background Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in... Abstract Background Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 506 |
| SubjectTerms | Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Antigens Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Aspirin Aspirin - administration & dosage Aspirin - therapeutic use Biological markers Biomarkers Cancer research Cancer therapies Cancer treatment Carcinoma Care and treatment Cell death Cervical cancer Cervical carcinoma Cervix Chemokines Chemoradiotherapy Chemotherapy Clinical trials Curcumin Curcumin - administration & dosage Curcumin - therapeutic use Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Cytokines Development and progression Dietary supplements Drug delivery Drug dosages Drug Repositioning Endometrial cancer Endometrial carcinoma Endometrial Neoplasms - therapy Endometrium Female Health aspects Humans Immune checkpoint Immune modulation Immune response Immune system Immunomodulation Immunosuppressive agents Immunotherapy Intestinal microflora Lansoprazole - administration & dosage Lansoprazole - therapeutic use Lymphocytes Medical prognosis Monoclonal antibodies Neoplasm Recurrence, Local - therapy Patients PD-1 blockade PD-1 protein PD-L1 protein Pembrolizumab Prognosis Quality of life Radiation Radiation (Physics) Radiation therapy Safety Sarcoma Sarcoma - therapy Study Protocol Survival Analysis Targeted cancer therapy Translation Treatment Outcome Tumor blood vessels Tumor microenvironment Tumors Uterine cancer Uterine Cervical Neoplasms - therapy Vaccines Vitamin D Vitamin D - administration & dosage Vitamin D - therapeutic use Womens health |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2ggEFISIiofsSJw608qi5SUVWo1JvlV2iFSKrd7E_gfzPjeFcbceDCNR5Lzsx4HvLMN4S8jtxZ7b0oeeuqsvIQw7kgZSlj23TC-TZ4bBQ--Vofn1dfLtTFzqgvrAmb4IEnxh0EyxFizQbNbMU6xK_T1keI6zupZJha91i7Saby-0Gjmc5vmFzXByuwwhqL1NpS1U1dypkXSmD9f5vkHZ80r5fccUBHd8jtHDnSw-nEd8mN2N8jN0_y2_h98vv0bAEWkibAWIr4CwMI-T219PoSXBVdLPIS6JhLYyHo6aeSUwfu7KcN8R1dIk4BCoraPtAr7BwZfg0hD_ii40BHiy_B1CcDA4dBOpwJAQegHvVn-YCcH33-_vG4zEMWSg-pz1jWIgodOq1tizC1UwLHvO7AhEatOqa09JV2lXehE5UNvFZd0HXgjgtWM_mQ7PVDHx8T2nrpua_AlAsHeWLTOiZDzcCCVrGByKIgbzdMN9cTloZJOYiuzSQhAxIyKCEjC_IBxbIlRBjs9AGUw2TlMP9SjoK8QKGaqad0e5nNoWrB1OHA1IK8ShQIhdFjrc0Pu16tzOLb2YzoTSbqBlAAb3PrAvw2omfNKPdnlHBX_Xx5o10m24qVgSAKYmjVajjuy-0y7sT6tz4Oa6RJXe6VVgV5NCnjljOSI46kgN3NTE1nrJuv9FeXCUkcBN4I1jz5H7x-Sm4JvGBMlULvk71xuY7PIGAb3fN0N_8ArH08lA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1taxQxEA56BfGL-N7VqlEEQVyaTfYl8Yu02tITWo7TQr-FvG1bxN3z9u4n-L-d2c2dXQS_bmYhm5l5ZmaTPEPI25BZI53jaaZsnuYOcjjrhUhFUFXNrVPe4UXh07Py5Dz_elFcxB9uXTxWucHEHqh96_Af-T6EGsg0CiXVp8WvFLtG4e5qbKFxm-xwqBT4hOwcHp3N5tt9hEoyGfcyM1nud4DGEg-rqbQoqzIVo2jUk_b_C803YtP43OSNQHR8n9yLGSQ9GFT-gNwKzUNy5zTukT8iv2fzKSAl7YljKfIwtKDsj9TQxRWELDqdxiH4btu3h6CzL2lGLYS1H8aHD3SJfAWoMGoaT6_xBkn7s_Wx0RddtXRlcEeYuh5oYDIoh70hYALUoR0tH5Pz46Pvn0_S2GwhdVACrdKSBy59LaVRSFc7FHLMyRqgNMiiZoUULpc2d9bXPDc-K4vay9JnNuOsZOIJmTRtE3YJVU64zOUA6dxCvVgpy4QvGSBpHirIMBLyfrPoejFwaui-FpGlHjSkQUMaNaRFQg5RLVtBpMPuH7TLSx29S3uTIQ-f8ZKZnNVIciiNC1D81aIQXiXkFSpVD3dLt06tDwoFkIeNUxPyppdASowGz9xcmnXX6em3-UjoXRSqWzAAZ-IVBvhsZNEaSe6NJMFn3Xh4Y106Ykan_1p4Ql5vh_FNPAfXhHaNMv1t91wWCXk6GON2ZUSGfJIc3q5GZjpauvFIc33VM4qDwivOqmf_n9Zzcpej67Ai5XKPTFbLdXgBKdnKvox-9wctWjWy priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9UwFA9zwtgX8W11ahRBEDvTJG1TQWQ-xq4wGdML-xby6jbUdt7bC_oH-H97Ttp7t-I--bU5gTTnTc75HUKehcwa5RxPs8rKVDqI4awXIhWhKmtuXeUdNgrvfy72pvLTUX60RpbjrYYLnF-a2uE8qens-_avn7_fgsK_iQqvildzsLEKS9CqNC_KIhVXyFWOuFxYySfPHxVKxdTwsHnptk2yITLE5Ivx5rmXimD-_5rsCz5rXE95wUHtXifXhsiS7vSicIOsheYm2dgf3s5vkT8HhxOwoDQCylLEZ2hBCF5TQ89OwJXRyWRYAhm0cWwEPfiQZtSCu_tmfHhJZ4hjgIykpvH0FDtL2h-tHwaA0a6lncGXYuqiAYLDIB3OjIADUIfyNbtNprsfv77fS4chDKmD1KhLCx648rVSpkIY2z7BY07VYGKDymuWK-GkstJZX3NpfFbktVeFz2zGWcHEHbLetE24R2jlhMucBFPPLeSRZWWZ8AUDCytDCZFHQl4sL12f9VgbOuYoqtA9szQwSyOztEjIO2TLihBhsuOHdnasB63T3mSIz2e8YkayGsEPlXEBksJa5MJXCXmMTNV9z-lK2fVOXoEpxIGqCXkaKRAqo8FanGOzmM_15MvhiOj5QFS3IADODK0N8NuIrjWi3BpRgi678fJSuvRSFTQEWRBj55WC4z5ZLeNOrI9rQrtAmtgFL1WekLu9MK5uZinTCSlHYjq6uvFKc3oSkcaB4SVn5f3_3vmAbHJUMJanXG2R9W62CA8hiuvso6ibfwGfk0Sd priority: 102 providerName: Scholars Portal |
| Title | PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31138229 https://www.proquest.com/docview/2243265989 https://www.proquest.com/docview/2231852485 https://pubmed.ncbi.nlm.nih.gov/PMC6537207 https://doaj.org/article/da18591ad80a40f08778ace495f353d9 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF61RUJcEO8aSlgQEhLCjV-7XnNrSqsGKVUUqFRxWe3DbiOIHeXxE_jfzKzXoRY3Lj5kx9Jm5-2d-YaQ92WslTAmCeNCZ2FmIIbTNk3DtCzyKtGmsAYbhSeX_OIq-3rNrvcI63phXNG-0fPj-tfiuJ7futrK5cIMuzqx4XRyyhnOVsmH-2QfBLRL0f3VQS4i4a8vY8GHazDAAuvTipDxnIc4OCeNEXnPRZV_fZGD7P_XMN_xTP2qyTtu6PwReejjR3rS7vMx2SvrJ-T-xN-QPyW_p7Mx2EnqYGMpojA0wOrPVNHlLTgsOh77JZA07YZD0OmXMKYanNpPZctPdIVoBcguqmpL59g_0iwa68d80U1DNwrvg6lxZgY2g3Q4GQI2QA1K0eoZuTo_-356EfpRC6GBBGgT8qRMhK2EUAWC1bZpXGREBYa0FKyKmEhNJnRmtK2STNmYs8oKbmMdJxGP0ufkoG7q8pDQwqQmNhkY9ERDtpgXOkotj8COZmUO8UVAPnaHLpctooZ0mYjgsmWWBGZJZJZMAzJCtuwIEQzb_dCsbqQXCWlVjCh8yopIZVGFEIdCmRJSvyplqS0C8gaZKtvO0p1KyxNWgMHDsakBeecoEBCjxoqbG7Vdr-X426xH9METVQ0IgFG-gQH-NmJo9SiPepSgsaa_3EmX9BZjLSGUgkiaFQK2-3a3jG9iFVxdNlukcb3umWABedEK4-5kOpkOSN4T097R9VdAvRyeuFenl__95ivyIEEFi1iYiCNysFlty9cQq230ADT0Oh-Qe6Ozy-ls4L54wHOSCXjORj8GTnf_AM-VQpE |
| link.rule.ids | 230,315,730,783,787,867,888,2109,2228,12070,21402,24332,27938,27939,31733,31734,33758,33759,43324,43819,53806,53808 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zb9QwELagSMAL4ialUIOQkBBWnTiHwwsqR7UL3aoqrbRvlq-0FWqy7PET-N_MON6lERKv8URyPDPfzMT2N4S88anR0tqMpbXJWW4hhzNOCCZ8XTWZsbWzeFF4clSOzvJv02Iaf7gt4rHKNSYGoHadxX_kexBqINMoall_nP1i2DUKd1djC42b5BbycCF3fjXdFFxpJbmMO5mpLPcWgMUSj6rVrCirkolBLAqU_f8C87XINDw1eS0MHdwn92L-SPd7hT8gN3z7kNyexB3yR-T38ckYcJIG2liKLAwdqPoD1XR2AQGLjsdxCL7ahOYQ9PgLS6mBoPZTO_-ezpGtANVFdevoJd4f6a46F9t80WVHlxr3g6kNMAOTQTnsDAEToBataP6YnB18Pf08YrHVArNQAC1ZmflMukZKXSNZbV_GcSsbAFIvi4YXUthcmtwa12S5dmlZNE6WLjVpxksunpCttmv9M0JrK2xqcwD0zEC1WNWGC1dywNHcV5BfJOTdetHVrGfUUKESkaXqNaRAQwo1pERCPqFaNoJIhh0edPNzFX1LOZ0iC592kuucN0hxKLX1UPo1ohCuTsguKlX1N0s3Lq32ixoAD9umJuR1kEBCjBZP3Jzr1WKhxj9OBkJvo1DTgQFYHS8wwGcjh9ZAcmcgCR5rh8Nr61IRMRbqr30n5NVmGN_EU3Ct71YoE-6657JIyNPeGDcrI1Jkk8zg7WpgpoOlG460lxeBTxwUXmW82v7_tHbJndHp5FAdjo--Pyd3M3QjXrBM7pCt5XzlX0BytjQvgwf-AbggNz0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3o9AoQYhISGym5cTh1tpWXWBrVaFShUXy4-kXZVNVrvZC3f-NzOOs2zg1ms8kZz48zcz8vgbQt4UoZJc68gPc5X4iYYYTpk49uMiz8pI6dxovCg8OUmPz5LP5-x8q9WXLdrXajaofs4H1ezS1lYu5nrY1YkNp5PDlGFvlWy4MOXwJrkFezbgXaLuDhAyeOQOMUOeDldAwxyr1HKfpVnqY_ucOET9PRtb_vVIVrj_f3re8k_92sktZzS6S350n9HWoFwN1o0a6F__KDxe6zvvkTsuRKUHrcl9cqOoHpDdiTuEf0h-T0_HQMXUKtNSFHqoAU0fqKSLS_CJdDx2QwBmZftP0OmRH1IFfvNKmuI9XaIgAiKCysrQGV5Rqee1cZ3EaFPTRuKRM9WWyWAyaIfNJ2ACVCNQl4_I2ejT98Nj33Vz8DXkWI2fRkXETcm5zFEPt80UA81L4OqCszJgPNYJV4lWpowSacKUlYanJlRhFKRB_JjsVHVVPCU017EOdQI-I1KQkGa5CmKTBkDVSZFBCOORd92KikUr2iFsssNT0SJBABIEIkHEHvmIa74xRL1t-6BeXgi3GsLIEIX-pOGBTIISVRS51AVkl2XMYpN7ZB8RI9rLqxvWEAcsB07FzqweeW0tUHOjwqKeC7lercT422nP6K0zKmtAl5bujgR8Nsp09Sz3epZACro_3EFXOFJaCYjWIFhnOYfpvtoM45tYaFcV9Rpt7HX6hDOPPGmRvvkz3YbxSNbbA71f1x8BZFvJcofkZ9d-c5_sTo9G4uv45MtzcjvCjRwwP-J7ZKdZrosXEBk26qXlgD_dFmGo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PRIMMO+study+protocol%3A+a+phase+II+study+combining+PD-1+blockade%2C+radiation+and+immunomodulation+to+tackle+cervical+and+uterine+cancer&rft.jtitle=BMC+cancer&rft.au=Tuyaerts%2C+Sandra&rft.au=Van+Nuffel%2C+An+M.+T.&rft.au=Naert%2C+Eline&rft.au=Van+Dam%2C+Peter+A.&rft.date=2019-05-28&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=19&rft_id=info:doi/10.1186%2Fs12885-019-5676-3&rft_id=info%3Apmid%2F31138229&rft.externalDBID=PMC6537207 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |